NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET.
馬里蘭州貝爾茨維爾，2024年11月26日 (全球新聞網) -- NextCure, Inc. (納斯達克: NXTC)是一家臨床階段的生物製藥公司，致力於發現和開發新的、首創的和最佳的癌症治療療法，今天宣佈將於12月5日星期四下午12:00在紐約市參加第36屆派傑投資醫療大會的爐邊聊天。
A live audio webcast will be available through the Investors section of the company's website at . A replay of the webcast will be available after the event and archived on the website for 30 days.
通過公司網站的投資者部分將提供實時音頻網絡直播，活動結束後，網絡直播的錄音將在網站上保存30天。
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response.
關於NextCure, Inc.
NextCure是一家臨床階段的生物製藥公司，專注於推進治療癌症患者的創新藥物，這些患者對目前的療法沒有反應或疾病進展，通過使用抗體藥物偶聯物、抗體和蛋白質等差異化的作用機制。我們專注於推進利用我們在理解生物途徑和生物標誌物、細胞之間的相互作用（包括在腫瘤微環境中）及每種相互作用在生物學反應中所起的作用方面的核心優勢的治療方法。
Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as "expects," "believes," "intends," "hope," "forward" and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and NextCure's dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
關於前瞻性聲明的警示聲明
本新聞稿中的觀點而非歷史事實的表述爲前瞻性聲明。諸如 "預期"，"相信"，"打算"，"希望"，"前進" 等表達旨在識別前瞻性聲明。前瞻性聲明涉及重大風險和不確定性，可能導致實際結果與任何前瞻性聲明中預期的結果有實質性差異。此類風險和不確定性包括但不限於：我們有限的經營歷史和無任何已獲得商業銷售批准的產品；我們巨額的虧損歷史；我們需要獲取額外融資；與臨床發展相關的風險，包括早期臨床數據可能得不到後續臨床結果的證實；臨床前研究結果可能得不到臨床試驗的證實；與市場批准和商業化相關的風險；以及nextcure對關鍵員工的依賴。更詳細的關於這些以及可能影響nextcure實際結果的其他因素的信息，請參閱nextcure提交給美國證券交易委員會（「SEC」）的文件，包括nextcure最新的10-k表和隨後的10-Q表。您不應過於依賴任何前瞻性聲明。即使預期發生變化，nextcure也無義務更新任何前瞻性聲明。
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
投資者查詢
蒂莫西·邁耶博士
nextcure公司。
首席運營官
(240) 762-6486
IR@nextcure.com
譯文內容由第三人軟體翻譯。
